CC-885

Home
Ligands
CC-885

Ligand id: 9224

Name: CC-885

Structure and Physico-chemical Properties

2D Structure

Calculated Physico-chemical Properties
Hydrogen bond acceptors	8
Hydrogen bond donors	3
Rotatable bonds	6
Topological polar surface area	107.61
Molecular weight	440.13
XLogP	1.94
No. Lipinski's rules broken	0

Molecular properties generated using the CDK

Classification
Compound class	Synthetic organic

IUPAC Name
3-(3-chloro-4-methylphenyl)-1-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]urea

IUPAC Name

3-(3-chloro-4-methylphenyl)-1-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]urea

Database Links
GtoPdb PubChem SID	340590211
PubChem CID	24788636
Search Google for chemical match using the InChIKey	DOEVCIHTTTYVCC-UHFFFAOYSA-N
Search Google for chemicals with the same backbone	DOEVCIHTTTYVCC
Search UniChem for chemical match using the InChIKey	DOEVCIHTTTYVCC-UHFFFAOYSA-N
Search UniChem for chemicals with the same backbone	DOEVCIHTTTYVCC

Comments
Structural studies have shown that immunomodulatory drugs bind in a shallow hydrophobic pocket on the surface of cereblon, mediated by a glutarimide ring. The broad activity profile of CC-885 is highly differentiated from that of thalidomide, lenalidomide and pomalidomide. The anti-tumour activity of CC-885 is mediated through the cereblon-dependent ubiquitination and degradation of the translation termination factor GSPT1. Patient-derived acute myeloid leukaemia tumour cells exhibit high sensitivity to CC-885, indicating the clinical potential of this mechanism [1].

Comments

Structural studies have shown that immunomodulatory drugs bind in a shallow hydrophobic pocket on the surface of cereblon, mediated by a glutarimide ring. The broad activity profile of CC-885 is highly differentiated from that of thalidomide, lenalidomide and pomalidomide. The anti-tumour activity of CC-885 is mediated through the cereblon-dependent ubiquitination and degradation of the translation termination factor GSPT1. Patient-derived acute myeloid leukaemia tumour cells exhibit high sensitivity to CC-885, indicating the clinical potential of this mechanism [1].